Abstract
Myasthenia gravis (MG) is an autoimmune disorder characterized by loss of acetylcholine receptors (AChR) due primarily to the production of anti-AChR autoantibodies. We report a case of MG associated with elevated anti-acetylcholine receptor antibody (anti-AChR Ab) and refractory crisis after thymectomy, in which immunoadsorption therapy was used successfully to stabilize myasthenic symptoms and decrease the anti-AChR Ab titer. A 79-year-old woman underwent extended thymectomy under the diagnosis of MG. One day after surgery she suddenly underwent a myasthenic crisis and was successfully resuscitated. Immunoadsorption therapy with a tryptophan-linked polyvinyl alcohol adsorber was performed three times for the purpose of decreasing the anti-AChR antibodies. The anti-AChR Ab titer was reduced by immunoadsorption during each therapy session; however, the level of anti-AChR Ab before immunoadsorption was higher than that of the previous treatment. This case suggests that the absolute serum level of anti-AChR Ab does not always correlate with the severity of the disease. Removal of pathogenic factors, not only anti-AChR Ab but other antibodies with specificities to skeletal muscles or certain components of the complement system, may contribute to effective treatment of myasthenic crisis.
Similar content being viewed by others
References
DB Drachman (1994) ArticleTitleMyasthenia gravis N Engl J Med 330 1797–810 Occurrence Handle10.1056/NEJM199406233302507 Occurrence Handle8190158
JM Lindstrom (2003) ArticleTitleNicotinic acetylcholine receptors of muscles and nerves: comparison of their structures, functional roles, and vulnerability to pathology Ann NY Acad Sci 998 41–52 Occurrence Handle10.1196/annals.1254.007 Occurrence Handle14592862
DB Drachman CW Angus RN Adams JD Michelson GJ Hoffman (1978) ArticleTitleMyasthenic antibodies cross-link acetylcholine receptors to accelerate degradation N Engl J Med 298 1116–1122 Occurrence Handle643030
N Shibuya T Sato M Osame T Takegami S Doi S Kawanami (1994) ArticleTitleImmunoadsorption therapy for myasthenia gravis J Neurol Neurosurg Psychiatry 57 578–581 Occurrence Handle8201327
A Watanabe T Watanabe T Obama T Mawatari H Ohsawa Y Ichimiya N Takahashi K Kusajima T Abe (2004) ArticleTitlePrognostic factors for myasthenic crisis after transsternal thymectomy in patients with myasthenia gravis J Thorac Cardiovasc Surg 127 868–876 Occurrence Handle10.1016/j.jtcvs.2003.07.036 Occurrence Handle15001919
F Romi GO Skeie JA Aarli NE Gilhus (2000) ArticleTitleMuscle autoantibodies in subgroups of myasthenia gravis patients J Neurol 247 369–375 Occurrence Handle10.1007/s004150050604 Occurrence Handle10896269
A Vincent J Bowen J Newsom-Davis J McConville (2003) ArticleTitleSeronegative generalized myasthenia gravis: clinical features, antibodies, and their targets Lancet Neurol 2 99–106 Occurrence Handle10.1016/S1474-4422(03)00306-5 Occurrence Handle12849266
W Hoch J McConville S Helms J Newsom-Davis A Melms A Vincent (2001) ArticleTitleAuto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies Nat Med 7 365–368 Occurrence Handle10.1038/85520 Occurrence Handle11231638
M Inoue K Kimura K Hasegawa K Fujiwara K Nakagawa T Yasumitsu (2002) ArticleTitleSteroid therapy without primary dose escalation for post-thymectomy crisis in 2 thymomatous myasthenia gravis patients Jpn J Thorac Cardiovasc Surg 50 165–167 Occurrence Handle11993198
Author information
Authors and Affiliations
About this article
Cite this article
Ishizeki, J., Nishikawa, K., Kunimoto, F. et al. Postoperative myasthenic crisis successfully treated with immunoadsorption therapy. J Anesth 19, 320–322 (2005). https://doi.org/10.1007/s00540-005-0335-z
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00540-005-0335-z